Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease

Bosco Paes, Brigitte Fauroux, Josep Figueras-Aloy, Louis Bont, Paul A Checchia, Eric A F Simões, Paolo Manzoni, Xavier Carbonell-Estrany, Bosco Paes, Brigitte Fauroux, Josep Figueras-Aloy, Louis Bont, Paul A Checchia, Eric A F Simões, Paolo Manzoni, Xavier Carbonell-Estrany

Abstract

Introduction: The REGAL (RSV evidence-a geographical archive of the literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This third publication covers the risk and burden of RSV infection in infants with chronic lung disease (CLD), formerly called bronchopulmonary dysplasia (BPD).

Methods: A systematic review was undertaken of publications between January 1, 1995 and December 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials.gov. Studies reporting data for hospital visits/admissions for RSV infection among infants with CLD/BPD who were not prophylaxed, as well as studies reporting RSV-associated morbidity, mortality, and healthcare costs, were included. Burdens of disease data were compared with preterm infants without CLD/BPD, other high-risk groups and term infants. Study quality and strength of evidence (SOE) were graded using recognized criteria.

Results: A total of 1837 studies were identified and 39 were included. CLD/BPD is a significant independent risk factor for RSV hospitalization [RSVH (odds ratio 2.2-7.2); high SOE]. Infants and young children with CLD/BPD had high RSVH rates which were generally similar in Europe, the United States, and Canada, mostly varying between 12 and 21%. Infants with CLD also had a longer length of hospital stay than other high-risk groups and term infants (high SOE). On average, infants spent 4-11 days in hospital (moderate SOE). Once hospitalized for RSV, affected children were at risk for a more severe course of disease than children with no RSVH (moderate SOE).

Conclusion: Severe RSV infection in infants and young children with CLD/BPD poses a significant health burden in Western countries. Further studies focussing on the burden of RSV infection in this well-recognized population at high risk for severe disease are needed to help improve outcomes and plan allocation of healthcare resources.

Funding: AbbVie.

Keywords: Bronchopulmonary dysplasia; Burden; Chronic lung disease; High-risk; Hospitalization; Morbidity; Preterm; Respiratory syncytial virus.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram. Epidemiology and burden of RSVH in infants with CLD/BPD. The third reviewer (B.R.G.) and X.C.E. were not required to resolve any disagreements during the review process

References

    1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–1555. doi: 10.1016/S0140-6736(10)60206-1.
    1. Hilgendorff A, Reiss I, Ehrhardt H, Eickelberg O, Alvira CM. Chronic lung disease in the preterm infant. Lessons learned from animal models. Am J Respir Cell Mol Biol. 2014;50:233–245.
    1. Piedmonte G, Perez MK. Respiratory syncytial virus and bronchiolitis. Pediatr Rev. 2014;35:519. doi: 10.1542/pir.35-12-519.
    1. Rietveld E, De Jonge HC, Polder JJ, Vergouwe Y, Veeze HJ, Moll HA, et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J. 2004;23:523–529. doi: 10.1097/01.inf.0000129690.35341.8d.
    1. Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, Medicines for Neonates Investigator Group et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS ONE. 2014;9:e89186. doi: 10.1371/journal.pone.0089186.
    1. Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed. 2005;90:F64–F68. doi: 10.1136/adc.2003.029710.
    1. Boyce TG, Mellen BG, Mitchel EF, Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865–870. doi: 10.1067/mpd.2000.110531.
    1. Berger TM, Aebi C, Duppenthaler A, Stocker M, Swiss Pediatric Surveillance Unit Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001–2005) Infection. 2009;37:109–116. doi: 10.1007/s15010-008-8130-z.
    1. American Academy of Pediatrics Committee on Infectious Diseases. American Academy of Pediatrics Bronchiolitis Guidelines Committee Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415–420. doi: 10.1542/peds.2014-1665.
    1. Robinson JL, Le Saux N, Canadian Paediatric Society. Infectious Diseases and Immunization Committee Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health. 2015;20:321–333.
    1. Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, Italian Society of Neonatology et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV) Ital J Pediatr. 2015;41:97. doi: 10.1186/s13052-015-0203-x.
    1. Figueras Aloy J, Carbonell Estrany X, Comité de Estándares de la SENeo et al. Update of recommendations on the use of palivizumab as prophylaxis in RSV infections. An Pediatr (Barc) 2015;82:199e1–199e2. doi: 10.1016/j.anpedi.2014.10.004.
    1. Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, et al. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother. 2011;17:254–263. doi: 10.1007/s10156-010-0121-1.
    1. Chi H, Hsu CH, Chang JH, Chiu NC, Hung HY, Kao HA, et al. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan. PLoS ONE. 2014;27(9):e100981. doi: 10.1371/journal.pone.0100981.
    1. AlAql F, Al-Hajjar S, Bin Mahoud L, Al-Alaiyan S, Tufenkji H, Abuzaid S, et al. Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia. Int J Pedatric Adolesc Med. 2016;3:38–42. doi: 10.1016/j.ijpam.2015.11.005.
    1. Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3:888–900. doi: 10.1016/S2213-2600(15)00255-6.
    1. Bont L, Checchia P, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther. 2016 (Epub ahead of print).
    1. Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A. 2014;100:145–157. doi: 10.1002/bdra.23235.
    1. Bancalari E. Is persistent need for supplemental oxygen a good indicator of adverse pulmonary outcome in very immature infants? Arch Dis Child Fetal Neonatal Ed. 2014;99:F254–F255. doi: 10.1136/archdischild-2013-305768.
    1. Jain D, Bancalari E. Bronchopulmonary dysplasia: clinical perspective. Birth Defects Res A. 2014;100:134–144. doi: 10.1002/bdra.23229.
    1. Northway WH, Jr, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline-membrane disease: bronchopulmonary dysplasia. N Engl J Med. 1967;276:357–368. doi: 10.1056/NEJM196702162760701.
    1. Maitre NL, Ballard RA, Ellenberg JH, Davis SD, Greenberg JM, Hamvas A, Prematurity and Respiratory Outcomes Program et al. Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach. J Perinatol. 2015;35:313–321. doi: 10.1038/jp.2015.19.
    1. Poindexter BB, Feng R, Schmidt B, Aschner JL, Ballard RA, Hamvas A, Prematurity and Respiratory Outcomes Program et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. Ann Am Thorac Soc. 2015;12:1822–1830. doi: 10.1513/AnnalsATS.201504-218OC.
    1. Walsh MC, Szefler S, Davis J, Allen M, Van Marter L, Abman S, et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics. 2006;117:S52–S56.
    1. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003;23:451–456. doi: 10.1038/sj.jp.7210963.
    1. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. . Accessed March 2016.
    1. OCEBM Levels of Evidence Working Group. The Oxford 2009 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. . Accessed March 2016.
    1. Viswanathan M, Berkman ND, Dryden DM, Hartling L. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI item bank. Methods Research Report. AHRQ Publication No. 13-EHC106-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2013. . Accessed March 2016.
    1. Ricart S, Marcos MA, Sarda M, Anton A, Muñoz-Almagro C, Pumarola T, et al. Clinical risk factors are more relevant than respiratory viruses in predicting bronchiolitis severity. Pediatr Pulmonol. 2012;48:456–463. doi: 10.1002/ppul.22633.
    1. Tatochenko V, Uchaikin V, Gorelov A, Gudkov K, Campbell A, Schulz G, et al. Epidemiology of respiratory syncytial virus in children ≤2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin Epidemiol. 2010;2:221–227.
    1. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162:230–236.
    1. Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999;104:894–899. doi: 10.1542/peds.104.4.894.
    1. Rossi GA, Medici MC, Merolla R, Osservatorio VRS Study Group Incidence of respiratory syncytial virus positivity in young Italian children referred to the emergency departments for lower respiratory tract infection over two consecutive epidemic seasons. Infection. 2005;33:18–24. doi: 10.1007/s15010-005-4010-y.
    1. Simon A, Müller A, Khurana K, Engelhart S, Exner M, Schildgen O, DSM RSV Paed Study Group et al. Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection—results from a prospective multicenter German surveillance study. Int J Hyg Environ Health. 2008;211:241–250. doi: 10.1016/j.ijheh.2007.07.020.
    1. Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UD, Osservatorio VRS Study Group et al. Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the Osservatorio VRS Study (2000–2004) New Microbiol. 2006;29:35–43.
    1. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-Aloy J, IRIS Study Group et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. Pediatr Infect Dis J. 2000;19:592–597. doi: 10.1097/00006454-200007000-00002.
    1. Wang EE, Law BJ, Robinson JL, Dobson S, Al Jumaah S, Stephens D, et al. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics. 1997;99:E9. doi: 10.1542/peds.99.3.e9.
    1. Eriksson M, Bennet R, Rotzén-Ostlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002;91:593–598. doi: 10.1111/j.1651-2227.2002.tb03282.x.
    1. Berner R, Schwoerer F, Schumacher RF, Meder M, Forster J. Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999. Eur J Pediatr. 2001;160:541–547. doi: 10.1007/s004310100801.
    1. Bonillo Perales A, Díez Delgado Rubio J, Ortega Montes A, Infante Márquez P, Jiménez Liria M, Batlles Garrido J, et al. Perinatal history and hospitalization for bronchiolitis. A comparison with the impact-RSV Study Group. An Esp Pediatr. 2000;53:527–532. doi: 10.1016/S1695-4033(00)77494-7.
    1. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003;88:1065–1069. doi: 10.1136/adc.88.12.1065.
    1. Weigl JA, Puppe W, Schmitt HJ. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis. 2001;20:452–459.
    1. Pezzotti P, Mantovani J, Benincori N, Mucchino E, Di Lallo D. Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy. BMC Pediatr. 2009;9:56. doi: 10.1186/1471-2431-9-56.
    1. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, Palivizumab Outcomes Registry Group Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28:511–517. doi: 10.1038/jp.2008.28.
    1. Pérez Pérez G, Navarro Merino M, Romero Pérez MM, Sáenz Reguera C, Pons Tubío A, Polo Padillo J. Respiratory morbidity after hospital discharge in premature infants born at < or =32 weeks gestation with bronchopulmonary dysplasia. An Pediatr (Barc) 2004;60:117–124. doi: 10.1016/S1695-4033(04)78231-4.
    1. Broughton S, Bhat R, Roberts A, Zuckerman M, Rafferty G, Greenough A. Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants. Arch Dis Child. 2006;91:26–30. doi: 10.1136/adc.2005.087270.
    1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723–1729. doi: 10.1164/ajrccm.163.7.2011060.
    1. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537. doi: 10.1542/peds.102.3.531.
    1. Pedersen O, Herskind AM, Kamper J, Nielsen JP, Kristensen K. Rehospitalization for respiratory syncytial virus infection in infants with extremely low gestational age or birthweight in Denmark. Acta Paediat. 2003;92:240–242. doi: 10.1111/j.1651-2227.2003.tb00533.x.
    1. Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, Burgess S, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child. 2001;85:463–468. doi: 10.1136/adc.85.6.463.
    1. Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants—implications for use of RSV immune globulin. Arch Dis Child. 2000;83:122–127. doi: 10.1136/adc.83.2.122.
    1. Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 2004;23:1081–1085.
    1. Groothuis JR, Fryzek JP, Makari D, Steffey D, Martone WJ. Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998–2008. Clin Epidemiol. 2011;3:245–250. doi: 10.2147/CLEP.S17189.
    1. Flamant C, Hallalel F, Nolent P, Chevalier JY, Renolleau S. Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation. Eur J Pediatr. 2005;164:93–98. doi: 10.1007/s00431-004-1580-0.
    1. Simon A, Ammann RA, Wilkesmann A, Eis-Hübinger AM, Schildgen O, Weimann E, DSM RSV Paed Study Group et al. Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr. 2007;166:1273–1283. doi: 10.1007/s00431-007-0426-y.
    1. Grimaldi M, Cornet B, Milou C, Gouyon JB. Prospective regional study of an epidemic of respiratory syncytial virus (RSV) bronchiolitis. Arch Pediatr. 2002;9:572–580. doi: 10.1016/S0929-693X(01)00923-X.
    1. Zaw W, McDonald J. Respiratory syncytial virus bronchiolitis in ex-preterm infants in the Scottish highlands: review of hospital admissions and an analysis of hospital cost. Scott Med J. 2003;48:108–110.
    1. Duppenthaler A, Gorgievski-Hrisoho M, Aebi C. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Swiss Med Wkly. 2001;131:146–151.
    1. Van de Steen O, Miri F, Gunjaca M, Klepac V, Gross B, Notario G, et al. The burden of severe respiratory syncytial virus disease among children younger than 1 year in Central and Eastern Europe. Infect Dis Ther. 2016 (Epub ahead of print).
    1. Arnold SR, Wang EE, Law BJ, Pediatric Investigators Collaborative Network on Infections in Canada et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatr Infect Dis J. 1999;18:866–869. doi: 10.1097/00006454-199910000-00006.
    1. Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89:673–678. doi: 10.1136/adc.2003.036129.
    1. Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, Gallardo-Pino C, Gil-de-Miguel A. Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain: epidemiology and comorbidities: an observational study. Medicine (Baltimore) 2015;94:e831. doi: 10.1097/MD.0000000000000831.
    1. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126:212–219. doi: 10.1016/S0022-3476(95)70547-3.
    1. Navas L, Wang E, de Carvalho V, Robinson J, Pediatric Investigators Collaborative Network on Infections in Canada Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr. 1992;121:348–354. doi: 10.1016/S0022-3476(05)90000-0.
    1. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116:1353–1360. doi: 10.1542/peds.2005-0249.
    1. McEvoy CT, Jain L, Schmidt B, Abman S, Bancalari E, Aschner JL. Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014;11(Suppl 3):S146–S153. doi: 10.1513/AnnalsATS.201312-424LD.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner